Keyword: Merck & Co.

Merck’s Keytruda finally has some immuno-oncology competition in first-line, non-small cell lung cancer, courtesy of Roche.

As officials scramble to contain an Ebola outbreak in the Democratic Republic of Congo, the WHO is worried that Merck's vaccine stockpile won't last.

The U.S. is supporting Merck in the Fosamax case, which addresses the question of whether FDA decisions shield pharma from state suits.

Based in Oxford and slated to open in 2022, the center will focus on creating rapid, cost-effective ways of developing and manufacturing vaccines.

Among small batch of price increases for the pharma giant was a 1.5% increase on superstar cancer drug Keytruda and 6% on HPV shot Gardasil.

After opening an office in Tampa, Florida, in 2014 and filling hundreds of positions, BMS plans to lay off dozens of employees there early next year.

Samsung BioLogics faces potential delisting; Merck will increase Gardasil supply to China; Chinese officials mulls new regulation for vaccine.

Merck kicked off a rolling FDA submission for its Ebola vaccine that's already been deployed against outbreaks in the Democratic Republic of Congo.

Merck’s Keytruda is looking to beat its immuno-oncology rivals into yet another market, and it just posted the data that could get the job done.

Here is some other vaccine news of note for the week.